We are live on
!
Find out more
ACA
Acorn Capital Advisors Portfolio holdings
AUM
$352M
1-Year Est. Return
299.18%
This Fund
S&P 500
This Quarter
Est. Return
-4.13%
1 Year Est. Return
+299.18%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$186M
AUM Growth
–
Cap. Flow
+$240M
Cap. Flow
% of AUM
129.03%
Top 10 Holdings %
Top 10 Hldgs %
79.24%
Holding
21
New
21
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CG Oncology
CGON
|
+$38.7M |
| 2 |
YMAB
Y-mAbs Therapeutics
YMAB
|
+$34.9M |
| 3 |
Q32 Bio
QTTB
|
+$25.4M |
| 4 |
OKUR
OnKure Therapeutics
OKUR
|
+$21.8M |
| 5 |
UroGen Pharma
URGN
|
+$18.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
CG Oncology
CGON
$6.28B
| $32.5M | 17.46% |
+1,131,501
| New | +$38.7M |
|
|
YMAB
2
DELISTED
Y-mAbs Therapeutics
YMAB
| $22.4M | 12.06% |
+2,861,825
| New | +$34.9M |
|
3
Candel Therapeutics
CADL
$733M
| $16.8M | 9.06% |
+1,939,644
| New | +$11.5M |
|
|
4
UroGen Pharma
URGN
$1.86B
| $16.1M | 8.69% |
+1,516,303
| New | +$18.2M |
|
5
Puma Biotechnology
PBYI
$404M
| $12M | 6.47% |
+3,940,052
| New | +$11.5M |
|
|
BCAX
6
Bicara Therapeutics
BCAX
$1.78B
| $11.2M | 6.03% |
+643,381
| New | +$13.4M |
|
|
TERN
7
DELISTED
Terns Pharmaceuticals
TERN
| $10.9M | 5.88% |
+1,971,264
| New | +$13.3M |
|
|
OKUR
8
OnKure Therapeutics
OKUR
$154M
| $10.2M | 5.51% |
+1,439,674
| New | +$21.8M |
|
9
Trevi Therapeutics
TRVI
$2.59B
| $8.24M | 4.44% |
+2,001,048
| New | +$6.41M |
|
10
Protara Therapeutics
TARA
$220M
| $6.76M | 3.64% |
+1,279,800
| New | +$4.13M |
|
|
HELP
11
Cybin Inc
HELP
$485M
| $6.48M | 3.49% |
+734,393
| New | +$7.46M |
|
12
Cardiff Oncology
CRDF
$66.5M
| $6.26M | 3.37% |
+1,442,308
| New | +$4.51M |
|
13
X4 Pharmaceuticals
XFOR
$375M
| $5.36M | 2.89% |
+243,688
| New | +$3.88M |
|
|
MURA
14
DELISTED
Mural Oncology
MURA
| $4.14M | 2.23% |
+1,286,079
| New | +$4.53M |
|
|
WHWK
15
Whitehawk Therapeutics
WHWK
$190M
| $3.62M | 1.95% |
+1,147,052
| New | +$2.6M |
|
|
OPTN
16
DELISTED
OptiNose
OPTN
| $2.82M | 1.52% |
+422,813
| New | +$3.72M |
|
|
17
Q32 Bio
QTTB
$466M
| $2.76M | 1.49% |
+803,425
| New | +$25.4M |
|
18
Acrivon Therapeutics
ACRV
$64.2M
| $2.44M | 1.31% |
+405,237
| New | +$2.94M |
|
19
BioAtla
BCAB
$5.46M
| $2.38M | 1.28% |
+80,641
| New | +$6.77M |
|
|
YARW
20
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
| $1.53M | 0.82% |
+9,139
| New | +$1.2M |
|
21
Verastem
VSTM
$510M
| $779K | 0.42% |
+779,498
| New | +$3.07M |
|
Similar funds
PIC
HIA
ES
EC
AW
MCMU
FWM
BL
Acorn Capital Advisors's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Acorn Capital Advisors, which disclosed 21 positions worth $186M. Its ten largest holdings account for 79% of the portfolio.
Its largest position is CG Oncology: 1,131,501 shares worth $32.5M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets.
- Acorn Capital Advisors's largest Q4 2024 buy was CG Oncology: 1,131,501 shares worth $32.5M.
- Acorn Capital Advisors's ten largest holdings make up 79% of its $186M portfolio in Q4 2024.
- Acorn Capital Advisors disclosed 21 positions in Q4 2024, its first 13F filing on record.
Based on Acorn Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.